Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
about
Structure of the human κ-opioid receptor in complex with JDTicSalvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonistStriatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine usersKappa-opioid ligands in the study and treatment of mood disordersNaltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in HumansBipolar disorder: candidate drug targets.Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution.Fear and the Defense Cascade: Clinical Implications and Management.A Kappa Opioid Model of Atypical Altered Consciousness and Psychosis: U50488, DOI, AC90179 Effects on Prepulse Inhibition and Locomotion in Mice.Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humansAcute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.Agonist-induced internalization of κ-opioid receptors in noradrenergic neurons of the rat locus coeruleusSalvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.Learning and memory impairment induced by salvinorin A, the principal ingredient of Salvia divinorum, in wistar rats.Respiratory rates and arterial blood-gas tensions in healthy rabbits given buprenorphine, butorphanol, midazolam, or their combinations.Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trialDepersonalization disorder: pharmacological approaches.Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men.Orexin/hypocretin role in reward: implications for opioid and other addictionsHuman psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats.PDYN rs2281285 variant association with drinking to avoid emotional or somatic discomfort.ΔFosB enhances the rewarding effects of cocaine while reducing the pro-depressive effects of the kappa-opioid receptor agonist U50488.Neuraxial opioid-induced itch and its pharmacological antagonismAsimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review.A single injection of a novel κ opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats.Effects of butorphanol on morphine-induced itch and analgesia in primates.Salvinorin A produces cerebrovasodilation through activation of nitric oxide synthase, κ receptor, and adenosine triphosphate-sensitive potassium channel.Opioid peptide-derived analgesicsSalvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans.Additive antinociceptive effects of mixtures of the κ-opioid receptor agonist spiradoline and the cannabinoid receptor agonist CP55940 in ratsCore outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendationsRoles of nucleus accumbens CREB and dynorphin in dysregulation of motivation.Orvinols with mixed kappa/mu opioid receptor agonist activityNeoclerodanes as atypical opioid receptor ligandsProfiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assaysDynorphin and the pathophysiology of drug addiction.The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward.Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability.
P2860
Q24308048-85D84FDA-1ABF-49ED-B0D6-98D9652C15C3Q24535736-5AE80280-CBA4-4815-B5D1-461E8AC94EBFQ24644973-1E6A846C-2B30-49B6-ADA3-CF364E17B916Q24657982-B6957425-8BA4-4E4E-8870-4F98F10C6296Q27300685-C413552D-D027-43AE-B2CE-35D0CC00F8FCQ28751133-C2186F57-2CD2-44EC-8A56-6CA7E7EAD47BQ30402789-CD12153D-7508-460A-B528-37BB828E17BFQ30406633-B41A9580-DC4D-4843-B164-D6C1D5A4083AQ30427779-9675E56D-33CB-4E75-B20F-A9BD125F30AAQ30447153-BE4C5031-51D0-4828-B0C2-9A6E850F8083Q34138291-A127410D-323F-4748-8ACC-F395A2783DF1Q34348578-C2966399-7006-435F-9123-E3C247942CD0Q34401390-36F821FC-96E9-41B5-9358-8E23674496ECQ34632744-D9A2957B-CC86-489B-BD9D-ACA42802E3F0Q34701337-45A9A300-FB6B-485B-B1B7-3500A68C6932Q34714459-07894A95-056D-48C0-B4D6-7CB326325E3CQ34726919-85A1C435-D71E-4D44-9EE1-7CDDC4AEC428Q34766451-8C1EB7B8-3EC9-4CBC-A785-250CCF189030Q34803483-184697F5-64C5-417A-A358-7B81CF7FA6A5Q34939568-B3AB74A3-69FB-4059-B242-E2F63C3D29EEQ34949512-FC982E71-36C2-4BF1-87BE-1FF25335024FQ35027648-FFA51188-17AB-4614-91E9-BF4E3A27F9F3Q35040224-FBC521E5-5721-4C53-8290-0D8480F96F1BQ35592974-F3A0FF37-3578-47A2-A899-28664ED34BF7Q35659494-1043569B-06D5-45AB-AA2B-7B630A7D7407Q35752958-016243AC-C2B9-4376-B40B-161E0446B531Q35837572-D7A9FBC4-0392-44D9-AEE4-C8BEF1608316Q36008808-11C499AC-96B8-4D0D-8251-74B19458BC85Q36069379-F1D25D05-DDE4-43BD-B560-5E0FC1DA5F65Q36341669-11BA4438-548D-44FB-BBBE-FA6ED705FFD7Q36363810-A35C3749-9ABB-4285-BAD6-BB44253CC044Q36387010-ADBBC6B2-A7FF-4358-9B6F-83E7C1901F72Q36389047-F0EDFB73-FABE-4253-BBD5-893E3F058BA9Q36554599-36940BF2-A01C-4C83-94BC-DFA9002F3EDAQ36822435-5FEA1E1E-F22A-4EDE-891F-C3AB57C914E6Q36899819-06B666B1-68F3-4E42-97ED-2CC3E03D833AQ36936203-2B40AA4D-69E6-487F-9A86-F1F97562482BQ36942175-D9025385-7913-4019-A29B-F5394F444833Q36992810-8F3A4F31-E98A-417E-93E3-FF7BBFE5EA3AQ37018703-D9374514-92D9-402E-82A1-7559017E0DBD
P2860
Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Enadoline, a selective kappa o ...... ol and hydromorphone in humans
@ast
Enadoline, a selective kappa o ...... ol and hydromorphone in humans
@en
Enadoline, a selective kappa o ...... ol and hydromorphone in humans
@nl
type
label
Enadoline, a selective kappa o ...... ol and hydromorphone in humans
@ast
Enadoline, a selective kappa o ...... ol and hydromorphone in humans
@en
Enadoline, a selective kappa o ...... ol and hydromorphone in humans
@nl
prefLabel
Enadoline, a selective kappa o ...... ol and hydromorphone in humans
@ast
Enadoline, a selective kappa o ...... ol and hydromorphone in humans
@en
Enadoline, a selective kappa o ...... ol and hydromorphone in humans
@nl
P2093
P3181
P356
P1433
P1476
Enadoline, a selective kappa o ...... ol and hydromorphone in humans
@en
P2093
E C Strain
G E Bigelow
P2888
P304
P3181
P356
10.1007/S002130100788
P407
P577
2001-09-01T00:00:00Z
P5875
P6179
1000910605